1
Isaiah Oladeji
Isaiah O Oladeji: Zinc oxide film and method for making. June 16, 2011: US20110143048-A1

A method for depositing a solid film of ZnO onto a substrate from a reagent solution includes a reservoir of reagent solution maintained at a sufficiently low temperature to inhibit homogeneous reactions within the reagent solution. The reagent solution contains a source of Zn, a source of 0, and mu ...


2
Isaiah Oladeji
Isaiah O Oladeji: Method for fabricating copper-containing ternary and quaternary chalcogenide thin films. June 16, 2011: US20110139071-A1

An apparatus for depositing a solid film onto a substrate from a reagent solution includes reservoirs of reagent solutions maintained at a sufficiently low temperature to inhibit homogeneous reactions within the reagent solutions. The chilled solutions are dispensed through showerheads, one at a tim ...


3
Somakumar R
Adnan Kutubuddin Bohori, Somakumar Ramachandrapanicker, Suma Memana Narayana Bhat: Systems for contactless power transfer. General Electric Company, June 16, 2011: US20110140429-A1

A system includes a first coil mechanically coupled to a first component and electrically coupled to a power source. The system further includes a second coil mechanically coupled to a second component and configured to receive power from the first coil via a magnetic field. At least one of the firs ...


4
Sagy Pundak Mintz
Tom James Haldes, Sagy P Mintz, Patricia A Messina, Alexander D Deitz: Synthetic Spread Trading. Trading Technologies International, June 16, 2011: US20110145165-A1

Synthetic spread trading strategies are represented and managed as homogeneous tradeable objects. Relationships between a synthetic spread and its constituent parts are defined and states for a spread are developed for accurately reporting, tracking and otherwise administering a synthetic spread and ...


5
Eugene Fitzgerald
Arthur J Pitera, Eugene A Fitzgerald, Steven A Ringel: Methods of forming high-efficiency multi-junction solar cell structures. June 16, 2011: US20110143495-A1

In various embodiments, solar cells include a junction including SiGe, a junction including at least one III-V material, and may be formed on silicon substrates and/or with silicon-based capping layers thereover.


6
CHU RONGMING: Reverse side engineered iii-nitride devices. TRANSPHORM, Borovoy Roger S, June 16, 2011: WO/2011/072027 (63 worldwide citation)

Group III-nitride devices are described that include a stack of III-nitride layers, passivation layers, and conductive contacts. The stack includes a channel layer with a 2DEG channel, a barrier layer and a spacer layer. One passivation layer directly contacts a surface of the spacer layer on a side ...


7
WATKINS JEFFRY DEAN: Aminoacyl trna synthetases for modulating inflammation. ATYR PHARMA, Rogel Mark E, June 16, 2011: WO/2011/072265 (56 worldwide citation)

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of ...


8
WATKINS JEFFRY DEAN: Aminoacyl trna synthetases for modulating hematopoiesis. ATYR PHARMA, Rogel Mark E, June 16, 2011: WO/2011/072266 (56 worldwide citation)

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such composition ...


9
RUE SARAH: Pcsk9 antagonists. Irm, Smith Timothy L, June 16, 2011: WO/2011/072263 (42 worldwide citation)

The present disclosure provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a ("PCSK9") and methods of using such antibodies.


10
TROIANO GREG: Stable formulations for lyophilizing therapeutic particles. BIND BIOSCIENCES, Kavanaugh Theresa C, June 16, 2011: WO/2011/072218 (35 worldwide citation)

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.